There has been no such ideal treatment targeting both stroke and AD because it has been believed for a long time that the pathogenesis of AD is solely due to Aβ and tau pathology, which is fundamentally different from the cerebral ischemia that causes acute brain neurovascular damage. The gene discussed is MAPT; the disease is stroke disorder.